Holst JJ (2006) Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 49(2):253–60

Drucker DJ, Habener JF, Holst JJ (2017) Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest 127(12):4217–27

Article  PubMed  PubMed Central  Google Scholar 

European Medicines Agency (EMA) (2018) Saxenda. [cited 2023 Nov 18]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda

European Medicines Agency (EMA) (2021) Wegovy. [cited 2023 Nov 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy

Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab 46:101102

Article  CAS  PubMed  Google Scholar 

Patoulias D, Popovic DS, Stoian AP, Janez A, Sahebkar A, Rizzo M (2023) Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: a systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials. J Diabetes Complications 37(8):108529

Article  CAS  PubMed  Google Scholar 

Mahapatra MK, Karuppasamy M, Sahoo BM (2022) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord 23(3):521–39

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389(24):2221–32

Article  CAS  PubMed  Google Scholar 

World Health Organization (WHO) (2021) Obesity and overweight. [cited 2023 Nov 18]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

GBD 2021 Diabetes Collaborators (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402(10397):203–34

Folkhälsomyndigheten (2023) Statistik om övervikt och fetma hos vuxna. [cited 2024 Feb 1]. Available from: https://www.folkhalsomyndigheten.se/livsvillkor-levnadsvanor/mat-fysisk-aktivitet-overvikt-och-fetma/overvikt-och-fetma/statistik-om-overvikt-och-fetma/overvikt-och-fetma-hos-vuxna/

Andersson T, Ahlbom A, Carlsson S (2015) Diabetes prevalence in Sweden at present and projections for year 2050. PLoS One 10(11):e0143084

Article  PubMed  PubMed Central  Google Scholar 

Hansson H (2023) Centrum för epedemiologi och samhällsmedicin Region Stockholm. [cited 2024 May 5]. Övervikt. Available from: https://www.folkhalsorapportstockholm.se/rapporten2/riskfaktorer/overvikt/

Carlsson AC, Wändell P, Ösby U, Zarrinkoub R, Wettermark B, Ljunggren G (2013) High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden - a challenge for public health. BMC Public Health 18(13):670

Article  Google Scholar 

Tandvårds- och läkemedelsförmånsverket (TLV) (2022) Uppföljning av läkemedelskostnader. Stockholm; Report No.: 1885/2022. Available from: https://www.tlv.se/download/18.2d24f53418120eae3ffcbc35/1655360166123/rapport_uppfoljning_av_lakemedelskostnader_2022_1885-2022.pdf

European Medicines Agency (EMA). EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens. [cited 2024 Jan 31]. Available from: https://www.ema.europa.eu/en/news/ema-alerts-eu-patients-and-healthcare-professionals-reports-falsified-ozempic-pens

Läkemedelsverket (2023) Förfalskat Ozempic på europeiska marknaden. [cited 2024 Feb 26]. Available from: https://www.lakemedelsverket.se/sv/nyheter/forfalskat-ozempic-pa-europeiska-marknaden

Iqbal J, Wu HX, Hu N, Zhou YH, Li L, Xiao F et al (2022) Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev 23(6):e13435

Article  CAS  PubMed  Google Scholar 

Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD (2022) Adverse drug reactions of GLP-1 agonists: a systematic review of case reports. Diabetes Metab Syndr: Clinical Res Rev 16(3):102427

Article  CAS  Google Scholar 

Läkemedelsverket (2023) Ozempic (semaglutid) och Victoza (liraglutid): Bristsituation. [cited 2024 Feb 8]. Available from: https://www.lakemedelsverket.se/4acb7c/globalassets/dokument/nyheter/dhpc/ozempic_victoza-semaglutid_liraglutid-dhpc-2023-11-20.pdf

Läkemedelsverket (2023) Ozempic (semaglutid) injektionsvätska, lösning i förfylld injektionspenna: bristsituation. [cited 2023 Nov 18]. Available from: https://www.lakemedelsverket.se/494174/globalassets/dokument/nyheter/dhpc/ozempic-semaglutide-dhpc-2023-03-13.pdf

Läkemedelsverket (2023) Förskriv inte diabetesläkemedel för viktnedgång. [cited 2024 Feb 13]. Available from: https://www.lakemedelsverket.se/sv/nyheter/forskriv-inte-diabeteslakemedel-for-viktnedgang

Nyheter SVT, Britts M, Lennen Merckx J (2024) Läkarna om Yazen: ”Helt förkastligt”. SVT Nyheter. [cited 2024 Jan 19]; Available from: https://www.svt.se/nyheter/inrikes/lakarna-om-yazen-helt-forkastligt

Torkelsson AC (2024) Reporter lyckades få ut Ozempic för viktnedgång på sex av nio nätkliniker. Läkartidningen. [cited 2024 Nov 10]. Available from: https://lakartidningen.se/aktuellt/nyheter/2024/09/reporter-lyckades-fa-ut-ozempic-for-viktnedgang-pa-sex-av-nio-natkliniker/

Uppdrag granskning: Jakten på Ozempic – 1. Godkänd för behandling. [cited 2024 Nov 10]. Available from: https://www.svtplay.se/video/ePvV6QJ/uppdrag-granskning-jakten-pa-ozempic/1-godkand-for-behandling

Helander I (2023) App-läkare skriver ut läkemedel för viktnedgång – trots normalvikt. Läkartidningen. [cited 2023 Nov 14]; Available from: https://lakartidningen.se/aktuellt/nyheter/2023/01/app-lakare-skriver-ut-lakemedel-for-viktnedgang-trots-normalvikt/

Linderoth PM (2024) Efter felaktig förskrivning av diabetesläkemedel – anmälan till Ivo. Läkartidningen. [cited 2024 Feb 13]. Available from: https://lakartidningen.se/aktuellt/patientsakerhet/2024/01/efter-felaktig-forskrivning-av-diabeteslakemedel-anmalan-till-ivo/

Han SH, Safeek R, Ockerman K, Trieu N, Mars P, Klenke A, et al (2023) Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google trends analysis. Aesthet Surg J. sjad211

Chiappini S, Vickers-Smith R, Harris D, Papanti Pelletier GD, Corkery JM, Guirguis A et al (2023) Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) pharmacovigilance Dataset. Pharmaceuticals (Basel) 16(7):994

Article  CAS  PubMed  Google Scholar 

Truveta Research (2023) Ozempic, Wegovy, and Mounjaro: on- and off-label prescribing trends. Truveta. [cited 2023 Nov 14]. Available from: https://www.truveta.com/blog/research/ozempic-wegovy-and-mounjaro/

Han SH, Ockerman K, Furnas H, Mars P, Klenke A, Ching J, et al (2024) Practice patterns and perspectives of the off-label use of GLP-1 agonists for cosmetic weight loss. Aesthet Surg J 44(4):NP279–306.

Watanabe JH, Kwon J, Nan B, Reikes A (2023) Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc S1544-3191(23)00309-6.

Törnblom M, State M (2024) Statistik över uttag av läkemedel med semaglutid. Socialstyrelsen; Report No.: 2024-4–9012. Available from: https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/statistik/2024-4-9012.pdf

Shmerling RH (2023) Harvard Health. [cited 2024 Feb 28]. What happens when a drug goes viral? Available from: https://www.health.harvard.edu/blog/what-happens-when-a-drug-goes-viral-202302212892

Trysell IH Katrin (2023) De nya fetmaläkemedlen – revolutionen som alla väntat på. Läkartidningen. [cited 2023 Nov 14]. Available from: https://lakartidningen.se/aktuellt/nyheter/2023/05/de-nya-fetmalakemedlen-revolutionen-som-alla-vantat-pa/

Trysell IH Katrin (2023) Experter: Nya effektiva fetmaläkemedlen ingen »quick fix« [Internet]. Läkartidningen. [cited 2024 Feb 24]. Available from: https://lakartidningen.se/aktuellt/nyheter/2023/05/experter-nya-effektiva-fetmalakemedlen-ingen-quick-fix/

Collins B (2023) New weight loss drugs trending with billionaires and celebrities are about to enter more American homes. CNBC. [cited 2024 Feb 24]; Available from: https://www.cnbc.com/2023/01/20/trending-glp-1-weight-loss-drugs-are-shipping-to-more-american-homes.html

Medaris A, Landsverk G (2023) Elon Musk says he used a popular weight-loss drug to get ‘fit, ripped, and healthy’. Business Insider. [cited 2024 Feb 24]. Available from: https://www.businessinsider.com/elon-musk-weight-loss-drug-wegovy-semaglutide-fit-ripped-healthy-2022-10

Davey M (2023) TGA investigates influencers after diabetes drug Ozempic promoted as weight-loss treatment. The Guardian. [cited 2023 Dec 6]; Available from: https://www.theguardian.com/australia-news/2023/jan/06/tga-investigates-influencers-after-diabetes-drug-ozempic-promoted-as-weight-loss-treatment

Region Stockholm. Befolkningsstatistik per år - Region Stockholm. [cited 2024 Jan 26]. Available from: https://www.regionstockholm.se/verksamhet/Regional-utveckling/statistik-och-analys/befolkning/befolkningsstatistik_per_ar/

Forslund T, Wettermark B (2019) Primärvårdens roll i sjukvårdssystemet [Internet]. Stockholm: Hälso- och sjukvårdsförvaltningen, Region Stockholm; p. 39. Available from: file:///C:/Users/Alice/Downloads/75_Prim%C3%A4rv%C3%A5rdens%20roll%20i%20sjukv%C3%A5rdssystemet%20FINAL.pdf

Läkemedelsverket (2020) Läkemedelsverkets syn på off label-förskrivning [Internet]. [cited 2023 Nov 19]. Available from: https://www.lakemedelsverket.se/sv/behandling-och-forskrivning/forskrivning/skriva-recept/lakemedelsverkets-syn-pa-off-label-forskrivning#hmainbody1

Wittich CM, Burkle CM, Lanier WL (2012) Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 87(10):982–90

Article  PubMed  PubMed Central  Google Scholar 

STAMP Commission Expert Group (2017) Off-label use of medicinal products. European Commission Directorate-General For Health And Food Safety; Report No.: STAMP 6/30. Available from: file:///C:/Users/Alice/Downloads/stamp6_off_label_use_background_0.pdf

Tandvårds- och läkemedelsförmånsverket (TLV) (2023) Regelverk. [cited 2023 Nov 19]. Available from: https://www.tlv.se/om-tlv/regelverk.html

Läkemedelsindustriföreningen (Lif) (2015) Läkemedelsförmån. [cited 2023 Nov 17]. Available from: https://www.lif.se/sa-funkar-det/lakemedelsforman/

Tandvårds- och läkemedelsförmånsverket (TLV) (2022) Olika typer av subvention - Tandvårds- och läkemedelsförmånsverket TLV. [cited 2025 Feb 2]. Available from: https://www.tlv.se/lakemedelsforetag/pris-och-subvention-av-lakemedel/olika-typer-av-subvention.html

Tandvårds- och läkemedelsförmånsverket (TLV). Förtydligad formulering av subventionsbegränsningen för GLP-1-receptoragonister. [cited 2023 Nov 17]. Available from: https://www.tlv.se/lakemedelsforetag/omprovning-av-lakemedel/arkiv-avslutade-omprovningar-lakemedel/2023-03-24-fortydligad-formulering-av-subventionsbegransningen-for-glp-1-receptoragonister.html

Zarrinkoub R, Wettermark B, Wändell P, Mejhert M, Szulkin R, Ljunggren G et al (2013) The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. European J of Heart Fail 15(9):995–1002

Article  Google Scholar 

Forslund T, Kosidou K, Wicks S, Dalman C (2020) Trends in psychiatric diagnoses, medications and psychological therapies in a large Swedish region: a population-based study. BMC Psychiatry 20(1):328

Article  CAS  PubMed  PubMed Central  Google Scholar 

Centrum för epidemiologi och samhällsmedicin. VAL-databaserna – Region Stockholm. [cited 2024 Jan 26]. Available from: https://www.folkhalsokollen.se/datakallor/val-databaserna/

Region Stockholm (2023) VAL databaserna: Datalager för uppföljning av vårdhändelser i Region Stockholm. Region Stockholm; [cited 2024 Feb 7]. Available from: https://www.regionstockholm.se/globalassets/1.-halsa-och-vard/forskning-och-innovation/valhandbok.pdf

Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U et al (2007) The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 16(7):726–35

Article  PubMed  Google Scholar 

Neilson LM, Munshi KD, Peasah SK, Huang Y, Swart ECS, Henderson R et al (2021) Changes in type 2 diabetes medication utilization and costs in the United States, 2014–2019. Med Care 59(9):789–94

Article  PubMed  Google Scholar 

Eberly LA, Yang L, Essien UR, Eneanya ND, Julien HM, Luo J et al (2021) Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum 2(12):e214182

Article  PubMed  PubMed Central  Google Scholar 

Carney G, Kim JD, O’Sullivan C, Thompson W, Bassett K, Levin J et al (2022) Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada. BMJ Open Diabetes Res Care 10(6):e002995

Article  PubMed  PubMed Central  Google Scholar 

Jermendy G, Kiss Z, Rokszin G, Abonyi-Tóth Z, Lengyel C, Kempler P et al (2022) Changing patterns of antihyperglycaemic treatment among patients with type 2 diabetes in Hungary between 2015 and 2020-nationwide data from a register-based analysis. Medicina (Kaunas) 58(10):1382

Article  PubMed